Table 3.
Adverse events | Propofol (n=100) | Etomidate (n=100) | Total (n=200) | p-value* |
---|---|---|---|---|
Major adverse events | 0 | 0 | 0 | 1.000 |
Minor adverse events | ||||
None | 38 (38.0) | 34 (34.0) | 72 (36.0) | 0.556 |
All cardiopulmonary adverse events | 65 (65.0) | 51 (51.0) | 116 (58.0) | 0.045 |
Oxygen desaturation | 4 (4.0) | 2 (2.0) | 6 (3.0) | 0.279 |
Respiratory depression | 5 (5.0) | 3 (3.0) | 8 (4.0) | 0.470 |
Transient hypotension | 42 (42.0) | 27 (27.0) | 69 (34.5) | 0.026 |
Transient hypertension | 6 (6.0) | 3 (3.0) | 9 (4.5) | 0.498 |
Arrhythmia during procedure | 0 | 0 | 0 | 1.000 |
Bradycardia | 1 (1.0) | 3 (3.0) | 4 (2.0) | 0.302 |
Tachycardia | 7 (7.0) | 13 (13.0) | 20 (10.0) | 0.157 |
Vital sign fluctuation | 46 (46.0) | 29 (29.0) | 75 (37.5) | 0.013 |
Adverse events disturbing procedure | 11 (11.0) | 20 (20.0) | 31 (15.5) | 0.079 |
Severe coughing | 2 (2.0) | 2 (2.0) | 4 (2.0) | 1.000 |
Belching | 1 (1.0) | 2 (2.0) | 3 (1.5) | 0.155 |
Needs for restraint | 4 (4.0) | 4 (4.0) | 8 (4.0) | 1.000 |
Myoclonus | 4 (4.0) | 12 (12.0) | 16 (8.0) | 0.037 |
Data are presented as number (%).
Significant differences between groups were tested by chi-square analysis.